Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U-ACHIEVE
NCT02819635Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in ulcerative colitis (UC) (10 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at 52 weeks. Started Sep 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02819635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819635.